Immunomic Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Immunomic Therapeutics's estimated annual revenue is currently $2.9M per year.
- Immunomic Therapeutics's estimated revenue per employee is $77,500
- Immunomic Therapeutics's total funding is $75.4M.
Employee Data
- Immunomic Therapeutics has 38 Employees.
- Immunomic Therapeutics grew their employee count by -33% last year.
Immunomic Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President & CEO | Reveal Email/Phone |
2 | CFO | Reveal Email/Phone |
3 | VP | Reveal Email/Phone |
4 | VP Quality Assurance | Reveal Email/Phone |
5 | VP Clinical Operations | Reveal Email/Phone |
6 | Director, Business Development | Reveal Email/Phone |
7 | Director, Cell Therapy Process Development | Reveal Email/Phone |
8 | Associate Director, Vaccine Discovery Research and Development | Reveal Email/Phone |
9 | Chief Scientific Officer (CSO) | Reveal Email/Phone |
10 | Director Clinical Operations | Reveal Email/Phone |
Immunomic Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.3M | 2 | -60% | N/A | N/A |
#2 | $2.9M | 38 | -31% | $17.5M | N/A |
#3 | $2.9M | 38 | -33% | $10.5M | N/A |
#4 | $19.8M | 128 | 0% | $69.4M | N/A |
#5 | $9.6M | 62 | -15% | N/A | N/A |
#6 | $1.4M | 9 | 0% | N/A | N/A |
#7 | $2.5M | 16 | 0% | N/A | N/A |
#8 | $7.4M | 48 | 0% | N/A | N/A |
#9 | $0.2M | 1 | -83% | N/A | N/A |
#10 | $1.7M | 11 | 22% | N/A | N/A |
What Is Immunomic Therapeutics?
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. This investigational technology has the potential to alter how we use immunotherapy for a number of diseases, including cancer, allergy and infectious diseases.
keywords:Biotechnology
$75.4M
Total Funding
38
Number of Employees
$2.9M
Revenue (est)
-33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Immunomic Therapeutics News
Immunomic Therapeutics to Participate at World Vaccine Congress Washington 2022. April 14, 2022 09:00 AM Eastern Daylight Time. ROCKVILLE, Md.--(BUSINESS...
Immunomic Therapeutics Reports Preclinical Data on Its MCP?V-LT and Her2/Neu DNA Vaccines at the American Association for Cancer Research (AACR)...
Immunomic Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022.
On January 14, 2021, Immunomic Therapeutics, Inc. closed the transaction. The company amended the terms of the transaction. On the same day, the company has received $16,428,230 in its third tranche, bringing total funding raised in the transaction to $77,728,230. The transaction included partic ...
Immunomic Therapeutics, Inc., a Rockville, Md.-based clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, closed a $61.3M financing. The round was led by HLB Co., LTD, a global pharmaceutical company focused on developing novel cancer drugs. This re ...
Other Companies in Rockville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.9M | 38 | -33% | $10.5M |
#2 | $8.2M | 38 | -5% | N/A |
#3 | $4.4M | 38 | -12% | N/A |
#4 | $6.7M | 38 | 3% | N/A |
#5 | $8.4M | 39 | 0% | N/A |